Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.
Pimavanserin (Nuplazid) is a novel antipsychotic with a narrow FDA-approval in psychosis due to Parkinson’s disease. This large randomized trial tested the drug in negative symptoms of schizophrenia.
Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.